PolyPid Ltd. (PYPD)

NASDAQ: PYPD · IEX Real-Time Price · USD
0.790
-0.020 (-2.43%)
At close: Feb 3, 2023, 4:00 PM
0.778
-0.012 (-1.51%)
After-hours: Feb 3, 2023, 7:55 PM EST
-2.43%
Market Cap 15.53M
Revenue (ttm) n/a
Net Income (ttm) -47.16M
Shares Out 19.66M
EPS (ttm) -2.48
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 92,549
Open 0.820
Previous Close 0.810
Day's Range 0.780 - 0.840
52-Week Range 0.650 - 6.900
Beta 1.26
Analysts Buy
Price Target 3.44 (+335.44%)
Earnings Date Feb 8, 2023

About PYPD

PolyPid Ltd., a late-stage biopharma company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in Phase III clinical trial for the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel. [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jun 26, 2020
Employees 75
Stock Exchange NASDAQ
Ticker Symbol PYPD
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for PYPD stock is "Buy." The 12-month stock price forecast is $3.44, which is an increase of 335.44% from the latest price.

Price Target
$3.44
(335.44% upside)
Analyst Consensus: Buy
Stock Forecasts

News

PolyPid to Report Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights on February 8, 2023

PETACH TIKVA, Israel, Jan. 31, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced th...

5 days ago - GlobeNewsWire

PolyPid Provides Positive Regulatory Update for D-PLEX₁₀₀ for the Prevention of Surgical Site Infections in Abdominal Colorectal Surgery

• Regulatory Pathway for a Potential NDA Submission Clarified Following Recent Interactions with the FDA

1 week ago - GlobeNewsWire

PolyPid Announces Publication in the American Journal of Surgery of Phase 2 Clinical Trial Post-hoc Analysis for D-PLEX₁₀₀ in the Prevention of Surgical Site Infections in Abdominal Surgery

D-PLEX 100 Achieved in Phase 2 Trial Significant Reduction in SSIs in Patients with Multiple Preoperative Risk Factors Versus Standard of Care

1 month ago - GlobeNewsWire

PolyPid Announces Receipt of Nasdaq Minimum Bid Price Notification

PETACH TIKVA, Israel, Dec. 09, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced it...

2 months ago - GlobeNewsWire

PolyPid Announces Presentation of Phase 2 D-PLEX₁₀₀ Clinical Data at the First Triennial Meeting of the International Orthopaedic Trauma Association

D-PLEX₁₀₀ Infection Prevention Efficacy in Patients with Increased Risk for Surgical Wound Infections Including Multi-Drug Resistant Organisms (MDROs) will be Presented During a Podium Presentation D-...

2 months ago - GlobeNewsWire

PolyPid Provides Corporate Update and Reports Third Quarter 2022 Financial Results

PETACH TIKVA, Israel, Nov. 09, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (PolyPid or the Company), a late-stage biopharma company aiming to improve surgical outcomes, today provided a corpo...

3 months ago - GlobeNewsWire

PolyPid to Report Third Quarter 2022 Financial Results and Operational Highlights on November 9, 2022

PETACH TIKVA, Israel, Oct. 26, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced th...

3 months ago - GlobeNewsWire

PolyPid Announces Cost Reduction Plan

Reduction of Approximately 20% in Organization Headcount

3 months ago - GlobeNewsWire

PolyPid Announces Eligibility for European Medicines Agency Centralized Procedure for D-PLEX₁₀₀ for the Prevention of Surgical Site Infections in Abdominal Surgery

Centralized Procedure Allows for Submission of a Single Marketing Application to the European Medicines Agency that, if Approved, Would Allow D-PLEX 100 to be Marketed in All EU Member States

4 months ago - GlobeNewsWire

PolyPid Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Results for D-PLEX₁₀₀ in the Prevention of Surgical Site Infections in Abdominal Surgery

Intends to discuss the Clinical Outcomes and Next Steps for D-PLEX 100  for the Prevention of SSIs in Abdominal Surgery with the FDA and the EU Regulatory Authorities in Q1 2023

4 months ago - GlobeNewsWire

PolyPid Announces Presentation of Phase 2 D-PLEX₁₀₀ Clinical Data at the European Society for Coloproctology Scientific Conference

Efficacy Data of D-PLEX 100 in the Prevention of Post-Abdominal Surgery Incisional Infection will be Presented During a Podium Presentation

5 months ago - GlobeNewsWire

PolyPid Announces Top-line Results of Phase 3 SHIELD I Trial of D-PLEX₁₀₀ for the Prevention of Surgical Site Infections in Abdominal Surgery

SHIELD I Study did not Achieve its Primary Endpoint of Reduction in Surgical Site Infections and Mortality

5 months ago - GlobeNewsWire

Wall Street Analysts Think PolyPid Ltd. (PYPD) Could Surge 206%: Read This Before Placing a Bet

The mean of analysts' price targets for PolyPid Ltd. (PYPD) points to a 205.6% upside in the stock.

5 months ago - Zacks Investment Research

PolyPid Announces Presentation at the 2022 Military Health System Research Symposium

Efficacy Data of D-PLEX 100 in reduction of Surgical Site Infection in Surgical Trauma Injuries will be Presented During a Podium Presentation

5 months ago - GlobeNewsWire

All You Need to Know About PolyPid Ltd. (PYPD) Rating Upgrade to Buy

PolyPid Ltd. (PYPD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects.

6 months ago - Zacks Investment Research

Wall Street Analysts Believe PolyPid Ltd. (PYPD) Could Rally 223%: Here's is How to Trade

The mean of analysts' price targets for PolyPid Ltd. (PYPD) points to a 222.9% upside in the stock.

6 months ago - Zacks Investment Research

PolyPid Provides Corporate Update and Reports Second Quarter 2022 Financial Results

PETACH TIKVA, Israel, Aug. 10, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today provided a c...

6 months ago - GlobeNewsWire

PolyPid Announces Exclusive Licensing Agreement with ADVANZ PHARMA for the Commercialization of D-PLEX₁₀₀ in Europe

PolyPid to potentially receive over $110 million in upfront and milestone payments as well as royalties on net sales

6 months ago - GlobeNewsWire

PolyPid to Report Second Quarter 2022 Financial Results and Operational Highlights on August 10, 2022

PETACH TIKVA, Israel, July 27, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced th...

6 months ago - GlobeNewsWire

PolyPid Announces Presentation of Phase 2 D-PLEX₁₀₀ Clinical Data at the Midwest Surgical Association 2022 Annual Meeting

Efficacy Data of D-PLEX 100 in the Prevention of Post-Abdominal Surgery Incisional Infection in High-Risk Patients will be Presented During a Podium Presentation

6 months ago - GlobeNewsWire

PolyPid Announces Dikla Czaczkes Akselbrad Assumes Role of CEO

Company Previously Announced Planned CEO Transition Following Retirement of Amir Weisberg Company Previously Announced Planned CEO Transition Following Retirement of Amir Weisberg

7 months ago - GlobeNewsWire

PolyPid Hosting Key Opinion Leader Webinar on Managing the Cost of Surgical Site Infections

PETACH TIKVA, Israel, June 15, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced th...

8 months ago - GlobeNewsWire

PolyPid Announces Presentation of D-PLEX₁₀₀ Phase 2 Clinical Data at ASM Microbe 2022

Phase 2 clinical data on the efficacy of D-PLEX 100 in surgical site infection prevention in elective colorectal surgery will be presented during a poster presentation

8 months ago - GlobeNewsWire

PolyPid to Present at the JMP Securities 2022 Life Sciences Conference

PETACH TIKVA, Israel, June 02, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced t...

8 months ago - GlobeNewsWire